MedTrace Logo

ALFAOMEGA Master Observational Trial

NCT04120935 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2025-08-24

No results posted yet for this study

Summary

AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between tumor and host cells in a cohort of CRC patients, with the aim of understanding how their outcomes can be significantly improved (e.g. reduction of their chance of recurrence and survival improval). This clinical resource for integrative clinical data and sample collection will allow the molecular story-telling of CRC metastatic spread along time and space and the selection of appropriate patients for experimentally-driven trials.

Conditions

Interventions

OTHER

Observation

Prospective Observation of standard clinical practice.

Sponsors & Collaborators

  • IFOM ETS - The AIRC Institute of Molecular Oncology

    lead OTHER

Principal Investigators

  • Silvia Marsoni, MD · IFOM ETS - The AIRC Institute of Molecular Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04120935 on ClinicalTrials.gov